GlobeNewswire by notified

PCI Biotech and Immunicum Announce an Extension to Their Research Collaboration to Explore Novel Cancer Vaccination Treatments

Share

Oslo, Norway, November 30, 2021 - PCI Biotech Holding ASA (OSE: PCIB), a cancer focused biopharmaceutical company with a unique intracellular delivery technology via Photochemical Internalisation and Immunicum AB (publ; IMMU.ST), a biopharmaceutical company focused on hard-to-treat established tumors and the prevention of cancer recurrence, announced today an extension of their current collaboration.

The companies jointly research the possibility to overcome current hurdles in cancer immunotherapy by introducing tumor independent immune targets into the tumor microenvironment, in combination with vaccination or adoptive immunotherapies. The so-called Tumor Independent Antigen concept, which has been invented by Immunicum, could benefit from PCI Biotech’s antigen delivery technologies based on Photochemical Internalisation. Following the encouraging results of the first set of in vitro experiments, during which the delivery protocol of the combination treatment has been optimized, the companies have decided to move ahead to evaluate the novel therapeutic concept in animal models. While the first experiments were conducted by Immunicum, this further in vivo evaluation will be carried out by PCI Biotech.

Commenting on the announcement PCI Biotech’s CEO, Per Walday said: “The results of the initial collaborative experiments are encouraging, supporting the immune response enhancing capability of the fimaVacc platform technology. We are committed to this collaboration and are looking forward to the next series of experiments in animal models, which are aimed to generate data that could pave the way to a potential joint development program.”

Erik Manting, CEO of Immunicum added: “At Immunicum, we are continuously studying novel immunotherapy concepts aimed to address hard-to-treat established tumors and to overcome the limitations of currently available cancer therapies. In this collaboration, we are combining our know-how and technology basis with that of PCI Biotech to design potential novel therapeutic concepts and we look forward to advancing the collaboration through in vivo studies as an important next step.”

Please see attachment for the full press release.

Contact information:        
Per Walday, CEO        
pw@pcibiotech.no
Mobile: +47 917 93 429

AboutImmunicumAB
Immunicum is a biopharmaceutical company focused on hard-to-treat established tumors and the prevention of cancer recurrence, two key challenges in oncology. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based therapies for solid and blood-borne tumors. Based in Sweden and the Netherlands, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.com

About PCI Biotech
PCI Biotech is a biopharmaceutical late-stage clinical development company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms: fimaChem (enhancement of chemotherapeutics for localised treatment of cancer), fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics delivery).

Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company’s lead programme fimaChem consists of a pivotal study in bile duct cancer, an orphan indication with a high unmet need and without approved products. fimaVacc applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. fimaNAc utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.

For further information, please visit: www.pcibiotech.com

Forward-looking statements        
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Alation Welcomes Tim Harford OBE as Keynote Speaker at revAlation in London18.8.2022 09:00:00 CEST | Press release

World renowned behavioural economist joins The Very Group CDO to keynote Alation’s industry conference LONDON, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Alation Inc., the leader inenterprise data intelligence solutions, today announced that revAlation, its flagship industry conference for data professionals across EMEA, will take place on 4th October and 5th October at County Hall, London. The two-day event will feature data networking opportunities, data training, and keynotes from award winning economist, journalist, and broadcaster Tim Harford, and Chief Data Officer of The Very Group, Steve Pimblett. Tim Harford is a bestselling author of books about economics and data, and the writer of the award-winning Financial Times column, The Undercover Economist. Harford will keynote the event and discuss how to use data and economics in everyday life. Steve Pimblett is the Chief Data Officer at leading UK and Ireland online retailer, The Very Group. Pimblett is an experienced data professional, ha

Sampo plc: Disclosure Under Chapter 9 Section 5 of the Securities Market Act (BlackRock, Inc.)18.8.2022 08:30:00 CEST | Press release

SAMPO PLC STOCK EXCHANGE RELEASE 18 August 2022 at 9:30 am Sampo plc: Disclosure Under Chapter 9 Section 5 of the Securities Market Act (BlackRock, Inc.) Sampo plc (business code 0142213-3) has received a disclosure under Chapter 9, Section 5 of the Securities Markets Act, according to which the voting rights attached to Sampo A shares (ISIN: FI009003305) owned directly or indirectly by BlackRock, Inc. (USA tax ID 32-0174421) and its funds decreased on 16 August 2022 below five (5) per cent of Sampo plc’s total voting rights. Sampo's share capital comprises 533,261,351 shares, of which 533,061,351 are A shares and 200,000 are B shares. Each A share entitles its holder to one (1) vote and each B share to five (5) votes. Thus, the total number of votes is 534,061,351. Total positions of BlackRock, Inc and its funds subject to the notification: % of shares and voting rights (total of A)% of shares and voting rights through financial instruments (total of B)Total of both in % (A+B)Resultin

Systemair's Interim Report for the first quarter will be presented on August 2518.8.2022 08:00:00 CEST | Press release

Press Release, 18 August 2022 Systemair ABs (NASDAQ OMX Stockholm: SYSR) Interim Report Q1 for the financial year 2022/23 will be published at 13:00 CET on August 25, 2022. A telephone conference will be held at 13:30 CET on August 25, 2022. The report will be presented by Roland Kasper, CEO, and Anders Ulff, CFO. In order to participate in the telephone conference: Call 010-884 8016 alternative international call +44 20 3936 2999 and enter code 539199 minutes before start. The presentation will be published on group.systemair.com For further information contact: Roland Kasper, CEO, + 46 73 094 40 13 Anders Ulff, CFO, + 46 70 577 40 09 Systemair AB, SE-739 30 Skinnskatteberg, Sweden, +46 222 440 00, www.systemair.com Systemair in brief Systemair is a leading ventilation company with operations in 52 countries in Europe, North America, the Middle East, Asia, Australia and Africa. The Company had sales of SEK 9.6 billion in the 2021/22 financial year and today employs approximately 6,700

Ultimovacs Expands High Dose Cohort Size in TENDU Phase I Prostate Cancer Trial after Safety Review18.8.2022 08:00:00 CEST | Press release

The TENDU interim safety results from nine patients show no safety concernsTrial extended to enroll up to three additional patients at the highest dose levelTENDU designed to evaluate the Tetanus-Epitope Targeting (TET)-platform in patients with prostate cancer Oslo, 18August 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, has completed treatment of three patients at the highest dose cohort in the phase I TENDU trial without any safety concerns. Based on these results, the company plans to enroll up to three additional patients at the highest dose level. The Drug Safety Monitoring Board, a group of experts set up to monitor patient safety during a clinical trial, found no safety concerns in any of the three dose cohorts. A total of nine patients have now been treated; three at each dose level (40 mcg, 400 mcg and 960 mcg). Ultimovacs plans to enroll up to three additional patients at the highest dose level (960 mcg) pro

Systemairs rapport för det första kvartalet presenteras den 25 augusti18.8.2022 08:00:00 CEST | Pressemelding

Pressmeddelande 18 augusti 2022 Systemair ABs (NASDAQ OMX Stockholm: SYSR) delårsrapport Q1 för räkenskapsåret 2022/23 kommer att offentliggöras kl. 13:00 CET den 25 augusti 2022. En telefonkonferens arrangeras kl. 13:30 CET den 25 augusti 2022. Rapporten presenteras av Roland Kasper, CEO, samt Anders Ulff, CFO. För att delta i telefonkonferensen: Ring 010-884 8016 alt. internationellt +44 20 3936 2999 och uppge kod 539199 minuter före start. Presentationen publiceras på group.systemair.com För ytterligare information kontakta: Roland Kasper, CEO, + 46 73 094 40 13 Anders Ulff, CFO, + 46 70 577 40 09 Systemair AB, 739 30 Skinnskatteberg, 0222-440 00, www.systemair.com Systemair i korthet Systemair är ett ledande ventilationsföretag med verksamhet i 52 länder i Europa, Nordamerika, Mellanöstern, Asien, Australien och Afrika. Bolaget omsatte 9,6 miljarder kronor räkenskapsåret 2021/22 och har idag cirka 6 700 anställda. Sedan grundandet av Systemair 1974 har bolaget uppvisat positiva rör